FDA Compliance Policy for Combination Product Postmarketing Safety Reporting Immediately in Effect

标准简介

Compliance Policy for Combination Product Postmarketing Safety Reporting Immediately in Effect[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准，适用于United States。

标准截图

 

标准文档说明

标准文档类型为Compliance Policy for Combination Product Postmarketing Safety Reporting Immediately in Effect[附网盘链接]高清PDF版本（文字版），标准文档内可进行搜索，可以复制原文，可粘贴。

标准部分原文

Compliance Policy for Combination Product Postmarketing Safety Reporting Immediately in Effect Guidance for Industry and Food and Drug Administration Staff This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance. I. Introduction This guidance document is intended to assist Combination Product Applicants who are subject to the Combination Product Postmarketing Safety Reporting Final Rule (hereafter “combination product PMSR final rule,” “final rule,” or “rule”), issued on December 20, 2016 (81 FR 92603), and codified in 21 CFR Part 4, Subpart B. This guidance document discusses FDA’s compliance policy for the rule. FDA does not intend to enforce certain requirements under the rule, specifically 21 CFR 4.102(c) and (d), 4.104(b)(1) and (b)(2), and 4.105(b), for a period of time as discussed further in section III below. FDA intends to delay enforcement of these provisions to ensure that Combination Product Applicants have sufficient time to update reporting and recordkeeping systems and procedures, including their information technology systems, to comply with these requirements, and in doing so, have sufficient time to consider the recommendations and technical specifications that FDA intends to provide through guidance to support compliance. For all other provisions of 21 CFR Part 4, Subpart B, FDA intends to enforce (or continue enforcing) the requirements per its usual policies as of the compliance date provided in the final rule. FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required. II. Background In the Federal Register of December 20, 2016 (81 FR 92603), FDA published a final rule for postmarketing safety reporting (PMSR) for combination products as defined at 21 CFR 3.2(e). The combination product PMSR final rule applies to combination products that are subject to premarket review by FDA. The entities subject to the final rule are “Combination Product Applicants,” which are applicants that hold the only application for a combination product or all 1

网盘链接

百度网盘：https://pan.baidu.com/s/1R96X2sjsVK7FRbcwBxgO1w
提取码：n6w3